Davide Pastorelli

3.0k total citations · 1 hit paper
65 papers, 1.7k citations indexed

About

Davide Pastorelli is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Davide Pastorelli has authored 65 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 21 papers in Hepatology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Davide Pastorelli's work include Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer Genomics and Diagnostics (9 papers). Davide Pastorelli is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer Genomics and Diagnostics (9 papers). Davide Pastorelli collaborates with scholars based in Italy, United States and United Kingdom. Davide Pastorelli's co-authors include Fable Zustovich, Giuseppe Lombardi, Baek‐Yeol Ryoo, Paolo Abada, Andrew X. Zhu, Takuji Okusaka, Joon Oh Park, Túlio Pfiffer, Hyun Cheol Chung and Masatoshi Kudo and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer.

In The Last Decade

Davide Pastorelli

61 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Andrew X. Zhu, Joon Oh Park et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Davide Pastorelli Italy	19	723	496	458	391	313	65	1.7k
Ki Mun Kang South Korea	20	288 0.4×	501 1.0×	347 0.8×	413 1.1×	122 0.4×	71	1.4k
Zhongguo Zhou China	21	845 1.2×	489 1.0×	353 0.8×	325 0.8×	358 1.1×	87	1.7k
Hassan Malik United Kingdom	24	667 0.9×	958 1.9×	739 1.6×	502 1.3×	153 0.5×	81	1.8k
Yoshihiko Ooka Japan	22	1.0k 1.4×	316 0.6×	312 0.7×	333 0.9×	818 2.6×	79	1.9k
Jane Koh Hong Kong	16	849 1.2×	493 1.0×	236 0.5×	232 0.6×	568 1.8×	31	1.7k
Massimo Malagó Germany	21	751 1.0×	434 0.9×	665 1.5×	265 0.7×	635 2.0×	36	1.7k
Olatunji B. Alese United States	22	125 0.2×	1.3k 2.6×	770 1.7×	423 1.1×	281 0.9×	149	2.1k
Anne Durnez Belgium	14	731 1.0×	346 0.7×	436 1.0×	177 0.5×	483 1.5×	21	1.8k
Jianzhuang Ren China	18	241 0.3×	178 0.4×	526 1.1×	498 1.3×	115 0.4×	133	1.3k
Yu‐Yun Shao Taiwan	29	989 1.4×	968 2.0×	316 0.7×	470 1.2×	439 1.4×	146	2.4k

Countries citing papers authored by Davide Pastorelli

Since Specialization

Citations

This map shows the geographic impact of Davide Pastorelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davide Pastorelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davide Pastorelli more than expected).

Fields of papers citing papers by Davide Pastorelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davide Pastorelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davide Pastorelli. The network helps show where Davide Pastorelli may publish in the future.

Co-authorship network of co-authors of Davide Pastorelli

This figure shows the co-authorship network connecting the top 25 collaborators of Davide Pastorelli. A scholar is included among the top collaborators of Davide Pastorelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davide Pastorelli. Davide Pastorelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bannone, Elisa, Paola Gualtieri, Alessandro Giardino, et al.. (2024). Nutritional Intervention for the Elderly during Chemotherapy: A Systematic Review. Cancers. 16(16). 2809–2809. 1 indexed citations

Pelizzaro, Filippo, Vincenzo Dadduzio, Davide Pastorelli, et al.. (2019). Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease. 51(12). 1713–1719. 16 indexed citations

Chau, Ian, Joon Oh Park, Baek‐Yeol Ryoo, et al.. (2018). Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer. 119(1). 19–26. 27 indexed citations

Pastorelli, Davide, Aline S.C. Fabricio, Petros Giovanis, et al.. (2018). Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. Pharmacological Research. 132. 72–79. 112 indexed citations

Rimassa, Lorenza, María Reig, Giovanni Abbadessa, et al.. (2017). Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World Journal of Gastroenterology. 23(13). 2448–2448. 10 indexed citations

Zustovich, Fable & Davide Pastorelli. (2016). Therapeutic management of bone metastasis in prostate cancer: an update. Expert Review of Anticancer Therapy. 16(11). 1199–1211. 10 indexed citations

Pastorelli, Davide, Stefania Zovato, & Caterina Soldà. (2015). Denosumab after bone progression with zoledronic acid: a single center experience. Annals of Oncology. 26. vi122–vi122.

Zhu, Andrew X., Joon Oh Park, Baek‐Yeol Ryoo, et al.. (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 16(7). 859–870. 634 indexed citations breakdown →

Blandamura, Stella, et al.. (2015). Przetrwała hipoglikemia hiperinsulinemiczna współistniejąca z nieaktywnym wyspiakiem trzustki. Endokrynologia Polska. 66(4). 356–360. 7 indexed citations

10.

Antonuzzo, Lorenzo, Elisa Giommoni, Davide Pastorelli, et al.. (2015). Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World Journal of Gastroenterology. 21(23). 7281–7288. 10 indexed citations

11.

Beltrame, Valentina, Mario Gruppo, Davide Pastorelli, et al.. (2014). Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature. World Journal of Surgical Oncology. 12(1). 105–105. 24 indexed citations

12.

Vitale, Alessandro, Patrizia Boccagni, Giacomo Zanus, et al.. (2012). Sorafenib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation?. Transplantation Proceedings. 44(7). 1989–1991. 25 indexed citations

13.

Aapro, Matti, Alex Molassiotis, Mario Dicato, et al.. (2012). The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Annals of Oncology. 23(8). 1986–1992. 219 indexed citations

14.

Lonardi, Sara, et al.. (2011). Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Critical Reviews in Oncology/Hematology. 81(1). 38–48. 26 indexed citations

15.

Zustovich, Fable, Giuseppe Lombardi, Ornella Nicoletto, & Davide Pastorelli. (2011). Second-line therapy for refractory renal-cell carcinoma. Critical Reviews in Oncology/Hematology. 83(1). 112–122. 13 indexed citations

16.

Lombardi, Giuseppe, Fable Zustovich, Fabio Farinati, et al.. (2010). Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 117(1). 125–133. 40 indexed citations

17.

Pastorelli, Davide, Fable Zustovich, Giovanni Faggioni, et al.. (2009). Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma. Anti-Cancer Drugs. 21(2). 210–213. 5 indexed citations

18.

Amadori, A., Elisabetta Rossi, Rita Zamarchi, et al.. (2009). Circulating and Disseminated Tumor Cells in the Clinical Management of Breast Cancer Patients: Unanswered Questions. Oncology. 76(6). 375–386. 22 indexed citations

19.

Vitale, Alessandro, Michael L. Volk, Davide Pastorelli, et al.. (2009). Use of Sorafenib in Patients With Hepatocellular Carcinoma Before Liver Transplantation: A Cost-Benefit Analysis While Awaiting Data on Sorafenib Safety. Hepatology. 51(1). 165–173. 79 indexed citations

20.

Zustovich, Fable, G. Cartei, Stefania Zovato, et al.. (2007). A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors.. PubMed. 27(2). 1019–24. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact